CO6361946A2 - Combuinaciones antitumorales que contienen anticuperos que reconocen especificamente cd38 y vincristina - Google Patents
Combuinaciones antitumorales que contienen anticuperos que reconocen especificamente cd38 y vincristinaInfo
- Publication number
- CO6361946A2 CO6361946A2 CO11065408A CO11065408A CO6361946A2 CO 6361946 A2 CO6361946 A2 CO 6361946A2 CO 11065408 A CO11065408 A CO 11065408A CO 11065408 A CO11065408 A CO 11065408A CO 6361946 A2 CO6361946 A2 CO 6361946A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibody
- seq
- nos
- combination
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
1.- Una combinación farmacéutica que comprende un anticuerpo que reconoce específicamente CD38 y al menos vincristina, en la que dicho anticuerpo puede destruir una célula CD38+ por apoptosis, citotoxicidad mediada por células dependientes de anticuerpos (ADCC) y citotoxicidad dependiente del complemento (CDC).2.- La combinación de la reivindicación 1, en la que dicho anticuerpo es un anticuerpo humanizado.3.- La combinación de la reivindicación 2, en la que dicho anticuerpo comprende uno o más regiones determinantes de la complementariedad que tiene una secuencia de aminoácidos seleccionada del grupo constituido por las SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 y 36.4.- La combinación de la reivindicación 3, en la que dicho anticuerpo comprende al menos una cadena pesada y al menos una cadena ligera, en la que dicha cadena pesada tiene una secuencia de aminoácidos, representada por la SEQ ID NO: 66, y dicha cadena pesada comprende tres regiones secuenciales determinantes de la complementariedad que tienen las secuencias de aminoácidos representadas por las SEQ ID NOS: 13, 14 y 15, y en la que dicha cadena ligera tiene una secuencia de aminoácidos seleccionada del grupo de SEQ ID NOS: 62 y 64, y dicha cadena ligera comprende tres regiones secuenciales determinantes de la complementariedad que tienen secuencias de aminoácidos representadas por SEQ ID NOS: 16,17 y 18.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08291117A EP2191841A1 (en) | 2008-11-28 | 2008-11-28 | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6361946A2 true CO6361946A2 (es) | 2012-01-20 |
Family
ID=40627439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11065408A CO6361946A2 (es) | 2008-11-28 | 2011-05-26 | Combuinaciones antitumorales que contienen anticuperos que reconocen especificamente cd38 y vincristina |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8633301B2 (es) |
| EP (2) | EP2191841A1 (es) |
| JP (2) | JP2012510462A (es) |
| KR (1) | KR101733253B1 (es) |
| CN (1) | CN102264388B (es) |
| AR (1) | AR074220A1 (es) |
| AU (1) | AU2009321250B2 (es) |
| BR (1) | BRPI0922304B1 (es) |
| CA (1) | CA2744996C (es) |
| CL (1) | CL2011001255A1 (es) |
| CO (1) | CO6361946A2 (es) |
| CR (1) | CR20110281A (es) |
| DO (1) | DOP2011000118A (es) |
| EA (1) | EA026092B1 (es) |
| EC (1) | ECSP11011064A (es) |
| HK (1) | HK1164153A1 (es) |
| HN (1) | HN2011001420A (es) |
| IL (1) | IL213117A (es) |
| MA (1) | MA32895B1 (es) |
| MX (1) | MX2011005539A (es) |
| NI (1) | NI201100106A (es) |
| NZ (1) | NZ592992A (es) |
| PA (1) | PA8850001A1 (es) |
| PE (1) | PE20110821A1 (es) |
| SG (1) | SG171822A1 (es) |
| TN (1) | TN2011000163A1 (es) |
| TW (1) | TWI457124B (es) |
| UA (1) | UA105507C2 (es) |
| UY (1) | UY32265A (es) |
| WO (1) | WO2010061358A1 (es) |
| ZA (1) | ZA201103923B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| RU2595839C2 (ru) | 2010-09-27 | 2016-08-27 | МорфоСис АГ | Антитело к cd38 и леналидомид или бортезомиб для лечения множественной миеломы и nhl |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| RU2650618C2 (ru) | 2012-09-25 | 2018-04-16 | МорфоСис АГ | Комбинации и их применение |
| SG10201803288RA (en) * | 2013-10-31 | 2018-05-30 | Sanofi Sa | Specific anti-cd38 antibodies for treating human cancers |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) * | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| WO2015200626A1 (en) * | 2014-06-25 | 2015-12-30 | The Rockefeller University | Compositions and methods for rapid production of versatile nanobody repertoires |
| WO2016022589A2 (en) | 2014-08-08 | 2016-02-11 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| EP3191187B1 (en) | 2014-09-09 | 2021-07-28 | Janssen Biotech, Inc. | Combination therapies with anti-cd38 antibodies |
| KR102597989B1 (ko) | 2014-12-04 | 2023-11-02 | 얀센 바이오테크 인코포레이티드 | 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체 |
| MX2017014810A (es) | 2015-05-20 | 2018-05-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| CN107921018A (zh) * | 2015-06-11 | 2018-04-17 | 生态有限公司 | 药物组合及其应用 |
| IL256242B1 (en) | 2015-06-22 | 2024-05-01 | Janssen Biotech Inc | Combination therapies for HEME malignancies with anti-CD38 antibodies and sorbibin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| ES2912729T3 (es) | 2015-11-03 | 2022-05-27 | Janssen Biotech Inc | Formulaciones subcutáneas de anticuerpos anti-CD38 y sus usos |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| AU2018359527A1 (en) | 2017-10-31 | 2020-05-07 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| EP3938394A1 (en) | 2019-03-15 | 2022-01-19 | MorphoSys AG | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| CN112876563B (zh) | 2019-11-29 | 2022-08-16 | 康诺亚生物医药科技（成都）有限公司 | 药物组合物及其制备方法和应用 |
| CA3160502A1 (en) | 2019-12-05 | 2021-06-10 | Thomas Ballet | Formulations of anti-cd38 antibodies for subcutaneous administration |
| KR20230142834A (ko) | 2021-01-14 | 2023-10-11 | 모르포시스 아게 | 항-cd38 항체 및 이의 용도 |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| TW202321303A (zh) | 2021-07-19 | 2023-06-01 | 德商莫菲西斯公司 | 抗pla2r自體抗體媒介膜性腎病變之治療 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
| CZ294425B6 (cs) | 1997-04-14 | 2005-01-12 | Micromet Ag | Způsob výroby anti-humánního antigenového receptoru, anti-humánní antigenový receptor, řetězec VH a VL, souprava pro selekci anti-humánních antigenových receptorů a farmaceutická kompozice, obsahující uvedený receptor |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CA2329940A1 (en) * | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| JP2008504013A (ja) * | 2004-02-06 | 2008-02-14 | モルフォシス・アクチェンゲゼルシャフト | 抗ｃｄ３８ヒト抗体及びその用途 |
| ES2716874T3 (es) * | 2005-03-23 | 2019-06-17 | Genmab As | Anticuerpos contra cd38 para el tratamiento del mieloma múltiple |
| DK2081595T3 (da) * | 2006-09-26 | 2019-07-15 | Genmab As | Anti-cd38 plus corticosteroid plus et ikke-corticosteroid kemoterapeutikum til behandling af tumorer |
| US20080092384A1 (en) * | 2006-10-16 | 2008-04-24 | Schaake Mark D | Installation of Middle Bearing for a Crankshaft |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
-
2008
- 2008-11-28 EP EP08291117A patent/EP2191841A1/en not_active Ceased
-
2009
- 2009-11-25 UY UY0001032265A patent/UY32265A/es not_active Application Discontinuation
- 2009-11-25 AR ARP090104546A patent/AR074220A1/es not_active Application Discontinuation
- 2009-11-25 TW TW098140157A patent/TWI457124B/zh active
- 2009-11-25 PA PA20098850001A patent/PA8850001A1/es unknown
- 2009-11-27 EA EA201100867A patent/EA026092B1/ru unknown
- 2009-11-27 US US13/130,865 patent/US8633301B2/en active Active
- 2009-11-27 BR BRPI0922304-5A patent/BRPI0922304B1/pt active IP Right Grant
- 2009-11-27 PE PE2011001095A patent/PE20110821A1/es not_active Application Discontinuation
- 2009-11-27 KR KR1020117014747A patent/KR101733253B1/ko active IP Right Grant
- 2009-11-27 NZ NZ592992A patent/NZ592992A/xx not_active IP Right Cessation
- 2009-11-27 JP JP2011538093A patent/JP2012510462A/ja active Pending
- 2009-11-27 MX MX2011005539A patent/MX2011005539A/es active IP Right Grant
- 2009-11-27 SG SG2011037983A patent/SG171822A1/en unknown
- 2009-11-27 CA CA2744996A patent/CA2744996C/en not_active Expired - Fee Related
- 2009-11-27 AU AU2009321250A patent/AU2009321250B2/en active Active
- 2009-11-27 UA UAA201108057A patent/UA105507C2/uk unknown
- 2009-11-27 WO PCT/IB2009/055390 patent/WO2010061358A1/en active Application Filing
- 2009-11-27 CN CN200980149084.2A patent/CN102264388B/zh active Active
- 2009-11-27 EP EP09775303.2A patent/EP2370095B1/en active Active
-
2011
- 2011-04-07 TN TN2011000163A patent/TN2011000163A1/fr unknown
- 2011-04-28 DO DO2011000118A patent/DOP2011000118A/es unknown
- 2011-05-20 EC EC2011011064A patent/ECSP11011064A/es unknown
- 2011-05-24 IL IL213117A patent/IL213117A/en active IP Right Grant
- 2011-05-26 CR CR20110281A patent/CR20110281A/es unknown
- 2011-05-26 CO CO11065408A patent/CO6361946A2/es unknown
- 2011-05-27 HN HN2011001420A patent/HN2011001420A/es unknown
- 2011-05-27 CL CL2011001255A patent/CL2011001255A1/es unknown
- 2011-05-27 NI NI201100106A patent/NI201100106A/es unknown
- 2011-05-27 ZA ZA2011/03923A patent/ZA201103923B/en unknown
- 2011-06-13 MA MA33936A patent/MA32895B1/fr unknown
-
2012
- 2012-05-24 HK HK12105112.8A patent/HK1164153A1/xx not_active IP Right Cessation
-
2015
- 2015-04-09 JP JP2015080071A patent/JP6130871B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6361946A2 (es) | Combuinaciones antitumorales que contienen anticuperos que reconocen especificamente cd38 y vincristina | |
| AR074221A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y ciclofosfamida | |
| AR123876A2 (es) | Composición farmacéutica de anticuerpos anti-cgrp | |
| AR074219A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| AR084196A1 (es) | Composiciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 | |
| CO6331299A2 (es) | Proteinas de union a antigeno de factor de crecimiento tipo factor de crecimiento epidermico de union a heparina | |
| AR073425A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20190261A1 (es) | Anticuerpos que reconocen tau | |
| PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| CO6190543A2 (es) | Anticuerpos anti-factor d humanizados | |
| PE20141435A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| PE20110802A1 (es) | Un anticuerpo antagonista de pcsk9 | |
| CO6700829A2 (es) | Moduladores novedosos y métodos de uso | |
| CL2015001895A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| PE20121516A1 (es) | Antidotos de anticoagulantes | |
| AR059432A1 (es) | Anticuerpos anti-fgf19 y metodos que usan estos | |
| AR066164A1 (es) | Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf) | |
| AR109533A2 (es) | Anticuerpos anti-fractalkina o un fragmento de unión a la fkn de éste, composiciones que lo comprenden y métodos para tratar trastornos inflamatorios | |
| PE20142170A1 (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina | |
| ES2625823T3 (es) | Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo | |
| AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos |